Q-omics provides the consensus-scored RPL7P14 profile across patient tissues and cancer cell-line models. RPL7P14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL7P14 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, RPL7P14 RNA expression shows 8,282 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight OV, HNSC, and THYM as cancer lineages where RPL7P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7P14 survival associations across molecular data types. RPL7P14 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7P14 RNA expression–survival associations across cancer types. High RPL7P14 expression shows unfavorable associations in MESO, TGCT, ACC and READ, but favorable associations in OV and SKCM. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for RPL7P14 RNA expression.
This table summarizes RPL7P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7P14 shows lower tumor expression in THCA and higher tumor expression in HNSC, PAAD and LIHC. The HNSC box plot shows higher RPL7P14 RNA expression in tumor versus normal tissue (log2 FC = +0.066, t-test p = .006).
This table shows molecular features associated with RPL7P14 in patient tissues and cancer cell lines. In patient samples, RPL7P14 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
